These brands include ZIIHERA ® for HER2+ cancers, ZEPZELCA ® for small cell lung cancer, and RYLAZE ®, DEFITELIO ®, and VYXEOS ® for a range of hematological malignancies. As previously announced, Mr.
BOSTON and LONDON, March 20, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (Nasdaq: AKTX) (“Akari” or the “Company”), a biotechnology company developing next-generation precision bi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback